{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:30:38Z","timestamp":1789543838978,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":727,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1093\/annonc\/mdx499","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T11:10:26Z","timestamp":1504177826000},"page":"2725-2732","source":"Crossref","is-referenced-by-count":43,"title":["Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7565-7504","authenticated-orcid":false,"given":"E.","family":"Giovannetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Funel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gemelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Thunnissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.B.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Struys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Perrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.H.","family":"Matherly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx499_bb0010","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman international conference on mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0015","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0020","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate Synthase but not excision repair cross-complementation group-1 tumor expression predicts outcome in patients with mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0025","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx499_bb0030","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/JTO.0b013e318283da3e","article-title":"Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with mesothelioma","volume":"8","author":"Lustgarten","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/JTO.0b013e318287c224","article-title":"Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from mesothelioma","volume":"8","author":"Mairinger","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist Update"},{"key":"10.1093\/annonc\/mdx499_bb0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6605501","article-title":"The role of folate receptor alpha in the response of mesothelioma to pemetrexed-containing chemotherapy","volume":"102","author":"Nutt","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx499_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-015-0158-9","article-title":"Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia","volume":"8","author":"Wojtuszkiewicz","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0055","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1182\/blood-2005-10-4048","article-title":"Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss","volume":"107","author":"Kaufman","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdx499_bb0060","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/1535-7163.MCT-05-0243","article-title":"The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line","volume":"5","author":"Chattopadhyay","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdx499_bb0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cell.2006.09.041","article-title":"Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption","volume":"127","author":"Qiu","year":"2006","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdx499_bb0070","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-013-2094-0","article-title":"Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter","volume":"71","author":"Cherian","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx499_bb0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bbrc.2008.09.074","article-title":"PCFT\/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells","volume":"376","author":"Gonen","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdx499_bb0080","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1535-7163.MCT-08-0938","article-title":"Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line","volume":"8","author":"Diop-Bove","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdx499_bb0085","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx499_bb0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdx499_bb0095","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","article-title":"A phase-I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors","volume":"27","author":"Soria","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-14-205","article-title":"The pemetrexed-containing treatments in non-small-cell lung cancer: is \u2212\/low thymidylate synthase expression better than +\/high thymidylate synthase expression: a meta-analysis","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdx499_bb0105","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2014.59.9324","article-title":"Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized phase-II trial","volume":"33","author":"Sun","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx499_bb0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13148-015-0157-2","article-title":"Epigenetic treatment of solid tumours: a review of clinical trials","volume":"7","author":"Nervi","year":"2015","journal-title":"Clin Epigenet"},{"key":"10.1093\/annonc\/mdx499_bb0115","doi-asserted-by":"crossref","first-page":"e1019978","DOI":"10.1080\/2162402X.2015.1019978","article-title":"Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models","volume":"4","author":"Covre","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1093\/annonc\/mdx499_bb0120","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small-cell lung cancer","volume":"7","author":"Juergens","year":"2011","journal-title":"Cancer Discov"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/11\/2725\/24169020\/mdx499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:07:27Z","timestamp":1624694847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0923753419346162"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx499","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}